1. Home
  2. CHY vs SDGR Comparison

CHY vs SDGR Comparison

Compare CHY & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Convertible and High Income Fund

CHY

Calamos Convertible and High Income Fund

HOLD

Current Price

$12.84

Market Cap

896.9M

Sector

Finance

ML Signal

HOLD

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

HOLD

Current Price

$13.12

Market Cap

925.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHY
SDGR
Founded
2003
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
896.9M
925.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CHY
SDGR
Price
$12.84
$13.12
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$21.00
AVG Volume (30 Days)
205.0K
1.5M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
10.11%
N/A
EPS Growth
N/A
45.14
EPS
N/A
N/A
Revenue
N/A
$255,869,000.00
Revenue This Year
N/A
$0.76
Revenue Next Year
N/A
$4.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23.29
52 Week Low
$10.20
$10.95
52 Week High
$12.91
$27.63

Technical Indicators

Market Signals
Indicator
CHY
SDGR
Relative Strength Index (RSI) 70.74 59.98
Support Level $11.19 $11.08
Resistance Level N/A $13.33
Average True Range (ATR) 0.17 0.72
MACD 0.05 0.14
Stochastic Oscillator 91.46 86.24

Price Performance

Historical Comparison
CHY
SDGR

About CHY Calamos Convertible and High Income Fund

Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

Share on Social Networks: